Cantargia names Wolfram Dempke as chief medical officer
Swedish biotech Cantargia (Nasdaq Stockholm: CANTA) has appointed Wolfram Dempke as chief medical officer, replacing Morten Lind Jensen who leaves after a short stint in the role.
Dr Dempke, effective immediately, brings more than 30 years of experience in hematology and oncology across academia, clinical research and industry. He is professor at the University of Munich and Cambridge University Medical School, and has held leadership roles at Bristol Myers Squibb (NYSE: BMY), Merck Serono and AstraZeneca (LSE: AZN).
He has overseen numerous regulatory submissions for oncology therapies including dasatinib, ipilimumab, gefitinib and mogamulizumab. Cantargia stressed his experience in pancreatic cancer as a strong fit for its portfolio.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze